Results 121 to 130 of about 12,942 (170)
Some of the next articles are maybe not open access.
JAMA: The Journal of the American Medical Association, 1983
Ranitidine is an H2-receptor antagonist that was released recently for use in the treatment of acute duodenal ulcer disease, Zollinger-Ellison syndrome, and systemic mastocytosis with gastric hypersecretion. The pharmacokinetics, efficacy, adverse effects, and clinical utility of ranitidine are presented.
openaire +2 more sources
Ranitidine is an H2-receptor antagonist that was released recently for use in the treatment of acute duodenal ulcer disease, Zollinger-Ellison syndrome, and systemic mastocytosis with gastric hypersecretion. The pharmacokinetics, efficacy, adverse effects, and clinical utility of ranitidine are presented.
openaire +2 more sources
Annals of Internal Medicine, 1985
Excerpt To the editor: In the report by Bredfeldt and von Huene on another possible case of ranitidine hepatitis (1) two cited studies are misinterpreted.
openaire +2 more sources
Excerpt To the editor: In the report by Bredfeldt and von Huene on another possible case of ranitidine hepatitis (1) two cited studies are misinterpreted.
openaire +2 more sources
Annals of Internal Medicine, 1983
Ranitidine, a new H2-receptor blocking antihistamine, is pharmacokinetically similar to cimetidine, but its potency is about eightfold greater. The clinical response to ranitidine is more prolonged, largely because of potency and not kinetic advantage.
openaire +2 more sources
Ranitidine, a new H2-receptor blocking antihistamine, is pharmacokinetically similar to cimetidine, but its potency is about eightfold greater. The clinical response to ranitidine is more prolonged, largely because of potency and not kinetic advantage.
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1984
To the Editor.— Most physicians would agree that the development of H 2 -inhibitor drugs for peptic ulcer is a major advance in the treatment of this common disease. Furthermore, the physiological research stimulated by their availability has increased our understanding of ulcer pathogenesis.
openaire +2 more sources
To the Editor.— Most physicians would agree that the development of H 2 -inhibitor drugs for peptic ulcer is a major advance in the treatment of this common disease. Furthermore, the physiological research stimulated by their availability has increased our understanding of ulcer pathogenesis.
openaire +2 more sources
Australian & New Zealand Journal of Psychiatry, 1991
Three cases are described in which the cessation of the H2-antagonist ranitidine was followed by a rapid improvement in severe depressive symptoms. The literature concerning H2-receptor antagonists and depression is reviewed, and an alternative drug (omeprazole) for severe peptic ulceration is discussed.
openaire +2 more sources
Three cases are described in which the cessation of the H2-antagonist ranitidine was followed by a rapid improvement in severe depressive symptoms. The literature concerning H2-receptor antagonists and depression is reviewed, and an alternative drug (omeprazole) for severe peptic ulceration is discussed.
openaire +2 more sources
Hepatitis Associated with Ranitidine
Annals of Internal Medicine, 1984Excerpt Ranitidine (Zantac; Glaxo, Incorporated, Research Triangle Park, North Carolina) is a relatively new H2-receptor antagonist with a potency fourfold to eightfold that of Cimetidine.
openaire +2 more sources